Nkarta saw the highest growth of 1.99% in patent filings in May and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.66% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Nkarta‘s patent filings and grants. Buy the databook here.
Nkarta has been focused on protecting inventions in World Intellectual Property Organization(WIPO) with five publications in Q2 2024
The World Intellectual Property Organization(WIPO) Patent Office dominates the patent filings with nearly 62% of filings. The World Intellectual Property Organization(WIPO), European Patent Office(EPO), South Korea(KR), and United States(US) patent Office are among the top ten patent offices where Nkarta is filings its patents. Among the top granted patent authorities, Nkarta has 100% of its grants in United States(US).
University of Pennsylvania and Memorial Sloan Kettering Cancer Center could be the strongest competitors for Nkarta
Patents related to immuno-oncology and rare diseases lead Nkarta's portfolio
Nkarta has the highest number of patents in immuno-oncology followed by, rare diseases. For immuno-oncology, nearly 67% of patents were filed and 50% of patents were granted in Q2 2024.
Breast cancer related patents lead Nkarta portfolio followed by cervical cancer, and leukemia
Nkarta has highest number of patents in breast cancer followed by cervical cancer, leukemia, liver cancer, and lung cancer.
For comprehensive analysis of Nkarta's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.